- Conditions
- Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Afimoxifene, Core Biopsy, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
- Interventions
- oral placebo, afimoxifene, tamoxifen citrate, placebo gel
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
- Interventions
- Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
- Conditions
- Mammographically Dense Breast
- Interventions
- Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 40 Years to 69 Years · Female only
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Mammographic Breast Density
- Interventions
- 4-OH tamoxifen, Placebo
- Drug
- Lead sponsor
- BHR Pharma, LLC
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 17
- States / cities
- Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
- Conditions
- Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
- Interventions
- Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
- Conditions
- Breast Cancer
- Interventions
- 4-hydroxytamoxifen, breast imaging study, radiomammography
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois